Status:

COMPLETED

REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)

Lead Sponsor:

University of Glasgow

Collaborating Sponsors:

NHS Greater Glasgow and Clyde

Juvenile Diabetes Research Foundation

Conditions:

Diabetes Mellitus, Type 1

Eligibility:

All Genders

40+ years

Phase:

PHASE3

Brief Summary

The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (toward...

Eligibility Criteria

Inclusion

  • Type 1 Diabetes for five years or more\*
  • Age 40 years or above
  • 0 =\< HbA1c \<10.0% (53 - 86 mmol/mol)
  • AND 3 or more of the following ten CardioVascular Disease (CVD) risk factors:
  • BMI \>27 kg/m\^2
  • Current HbA1c \>8.0% (64 mmol/mol)
  • Known CVD/peripheral vascular disease
  • Current smoker
  • Estimated glomerular filtration rate (eGFR) \<90 ml/min per 1.73 m\^3
  • Confirmed micro- or macroalbuminuria \[according to local assays and reference ranges\]
  • Hypertension (BP \>=140/90 millimeters of mercury (mmHg) or established on antihypertensive treatment)
  • Dyslipidaemia \[total cholesterol \>=5.0 mmol/L (200 mg/dL);OR HDL cholesterol \<1.20 mmol/L (46mg/dL) \[MEN\]; OR \<1.30 mmol/L (50 mg/dL) \[WOMEN\]; or triglycerides \>=1.7 mmol/L (150mg/dL); or established on lipid-lowering treatment)\]
  • Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling with myocardial infarction or stroke aged \<60 years)
  • Duration of diabetes \> 20 years

Exclusion

  • eGFR \< 45 ml/min/1.73m2
  • woman of childbearing age not on effective contraception
  • Pregnancy and/or lactation
  • Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three months
  • NYHA stage 3 or 4 heart failure
  • Significant hypoglycaemia unawareness
  • Impaired cognitive function/ unable to give informed consent
  • Previous carotid surgery/ inability to capture adequate carotid images
  • Estimated glomerular filtration \< 45ml/min/1.73m\^2 (MDRD)
  • Gastroparesis
  • History of lactic acidosis
  • Other contraindications to metformin (hepatic impairment, known hypersensitivity to metformin, acute illness such as dehydration, severe infection, shock, acute cardiac failure or suspected tissue hypoxia)
  • Any coexistent life threatening condition including prior diagnosis of cancer within two years
  • History of alcohol problem or drug abuse

Key Trial Info

Start Date :

December 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 18 2017

Estimated Enrollment :

493 Patients enrolled

Trial Details

Trial ID

NCT01483560

Start Date

December 1 2011

End Date

April 18 2017

Last Update

June 19 2019

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

Royal Melbourne Hospital

Melbourne, Australia

2

St Vincent's Hospital

Melbourne, Australia

3

Royal Prince Albert Hospital

Sydney, Australia

4

St Joseph's Health Care

London, Ontario, Canada